Expanding Polycyclic Tetramate Macrolactam (PoTeM) Core Structure Diversity by Chemo‐Enzymatic Synthesis and Bioengineering
Angewandte Chemie International Edition · 24.03.2025 · 64 (13)
DOI: 10.1002/anie.202420335 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 27.02.2025. Verfasst von Sebastian Schuler und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chair of Technical Biochemistry, Technische Universität Dresden, Bergstraße 66, 01069, Dresden, Germany. Hauptthemen laut MEDLINE: Polyketide Synthases, Bioengineering, Lactams, Macrocyclic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, H2020 Marie Skłodowska-Curie Actions.
Abstract (Originalsprache)
Polycyclic tetramate macrolactams (PoTeMs) represent a growing class of bioactive natural products that are derived from a common tetramate polyene precursor, lysobacterene A, produced by an unusual bacterial iterative polyketide synthase (PKS)/non‐ribosomal peptide synthetase (NRPS). The structural and functional diversity of PoTeMs is biosynthetically elaborated from lysobacterene A by pathway‐specific cyclizing and modifying enzymes. This results in diverse core structure decoration and cyclization patterns. However, approaches to directly edit the PoTeM carbon skeleton do currently not exist. We thus set out to modify the PoTeM core structure by exchanging the natural l ‐ornithine‐derived building block by l ‐lysine, hence extending macrocycle size by an additional CH 2 group. We developed streamlined synthetic access to lysobacterene A and the corresponding extended analog and achieved cyclization of both precursors by the cognate PoTeM cyclases IkaBC in vitro. This chemo‐enzymatic approach corroborated the catalytic competence of IkaBC to produce a larger macrolactam yielding homo‐ikarugamycin. We thus engineered the adenylation domain active site of IkaA to directly accept l ‐lysine, which upon co‐expression with IkaBC delivered a recombinant bacterial homo‐ikarugamycin producer. Our work establishes an entirely new PoTeM structural framework and sets the stage for the biotechnological diversification of the PoTeM natural product class in general.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chair of Technical Biochemistry, Technische Universität Dresden, Bergstraße 66, 01069, Dresden, Germany.
- Department of Natural Product Biotechnology, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) and Department of Pharmacy at Saarland University, PharmaScienc…
- Department of Chemistry, Ludwig-Maximilians-Universität München, Butenandtstraße 5-13, 81377, Munich, Germany.
ORCID-Profile: Manuel Einsiedler, Tobias A M Gulder
Förderung
- Deutsche Forschungsgemeinschaft
- H2020 Marie Skłodowska-Curie Actions
Zitieren
APA
Schuler, S., Einsiedler, M., Evers, J. K., Malay, M., Uka, V., Schneider, S., & Gulder, T. A. M. (2025). Expanding Polycyclic Tetramate Macrolactam (PoTeM) Core Structure Diversity by Chemo‐Enzymatic Synthesis and Bioengineering. Angewandte Chemie International Edition, 64(13). https://doi.org/10.1002/anie.202420335
Vancouver
Schuler S, Einsiedler M, Evers JK, Malay M, Uka V, Schneider S, et al. Expanding Polycyclic Tetramate Macrolactam (PoTeM) Core Structure Diversity by Chemo‐Enzymatic Synthesis and Bioengineering. Angewandte Chemie International Edition. 2025;64(13). doi:10.1002/anie.202420335
BibTeX
@article{Schuler2025,
author = {Schuler, Sebastian and Einsiedler, Manuel and Evers, Julia K and Malay, Mert and Uka, Valdet and Schneider, Sabine and Gulder, Tobias A M},
title = {Expanding Polycyclic Tetramate Macrolactam (PoTeM) Core Structure Diversity by Chemo‐Enzymatic Synthesis and Bioengineering},
journal = {Angewandte Chemie International Edition},
year = {2025},
volume = {64},
number = {13},
doi = {10.1002/anie.202420335}
}
EUVIMED